Inmune Bio, Inc. (INMB) stock
INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.83−0.07 (-7.50%)
Close on Nov 20, 2026Market cap $22.95MP/E –Yield –
Inmune Bio free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Inmune Bio's free cash flow for the twelve months ending Dec 31, 2025 was -$23.62M. For fiscal 2025 it was -$23.62M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$23.62M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$3.09M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.63M | – |
See a number that looks wrong?